Chad Blunt, MD
Family Medicine · Oak Harbor, OHNPI 1447345301
Payments from drug & device makers
Across 490 payments — averaging $15.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$978
- AbbVie$791
- Novo Nordisk$736
- Boehringer Ingelheim$657
- Lilly USA, LLC$599
- Amgen$387
- plus $4K from 31 others
What the payments were for
- Food & beverage$7,655100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $978 |
| AbbVie(2 entities) | 46 | $791 |
| Novo Nordisk | 53 | $736 |
| Boehringer Ingelheim | 37 | $657 |
| Lilly USA, LLC | 45 | $599 |
| Amgen | 23 | $387 |
| Pfizer | 34 | $378 |
| Merck | 20 | $246 |
| GSK | 16 | $235 |
| Bayer | 12 | $204 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $202 |
| Johnson & Johnson | 14 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $186 |
| Kowa Pharmaceuticals America, Inc. | 12 | $183 |
| Biohaven Pharmaceuticals, Inc. | 11 | $180 |
| Novartis | 11 | $176 |
| E.r. Squibb & Sons, L.L.C. | 11 | $166 |
| Esperion Therapeutics, Inc. | 8 | $119 |
| Teva Pharmaceuticals USA, Inc. | 8 | $112 |
| Astellas Pharma US Inc | 7 | $103 |
| Otsuka America Pharmaceutical, Inc. | 5 | $99 |
| Phathom Pharmaceuticals, Inc. | 2 | $87 |
| Amarin Pharma, Inc. | 5 | $85 |
| Exact Sciences | 4 | $85 |
| Sanofi-aventis U.S. LLC | 4 | $81 |
| Eisai Inc. | 5 | $73 |
| Idorsia Pharmaceuticals US Inc | 5 | $71 |
| Abbott | 3 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Lundbeck LLC | 2 | $30 |
| Almatica Pharma LLC | 2 | $26 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Biogen | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$7,686 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 127 | $117,715 |
| OzempicSemaglutide | 36 | $50,913 |
| JardianceEmpagliflozin | 43 | $37,218 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $32,478 |
| FarxigaDapagliflozin Propanediol | 26 | $25,160 |
| VraylarCariprazine Hcl | 18 | $24,952 |
| RybelsusSemaglutide | 17 | $23,508 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $20,157 |
| XareltoRivaroxaban | 13 | $19,573 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $13,666 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $13,654 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 16 | $6,779 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,262 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $6,078 |
| Pantoprazole Sodium | 342 | $5,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $378 | $117,715127 claims |
| Novo NordiskOzempic, Rybelsus | $736 | $74,42153 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere, Symbicort | $978 | $48,58766 claims |
| Boehringer IngelheimJardiance | $657 | $37,21843 claims |
| GSKTrelegy Ellipta | $235 | $32,47834 claims |
| AbbVieVraylar, Synthroid | $791 | $26,72779 claims |
| MerckJanumet | $246 | $20,15717 claims |
| Johnson & JohnsonXarelto | $196 | $19,57313 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $186 | $6,26213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Oak Harbor
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.